KR20150139620A - 이소포스포르아미드 머스타드의 염 및 이의 동족체 - Google Patents

이소포스포르아미드 머스타드의 염 및 이의 동족체 Download PDF

Info

Publication number
KR20150139620A
KR20150139620A KR1020157033501A KR20157033501A KR20150139620A KR 20150139620 A KR20150139620 A KR 20150139620A KR 1020157033501 A KR1020157033501 A KR 1020157033501A KR 20157033501 A KR20157033501 A KR 20157033501A KR 20150139620 A KR20150139620 A KR 20150139620A
Authority
KR
South Korea
Prior art keywords
ipm
dose
tris
tumor
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157033501A
Other languages
English (en)
Korean (ko)
Inventor
존 씨. 아메디오
바바라 피. 월너
필립 비. 코마르니트스키
Original Assignee
지오팜 온콜로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39387443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150139620(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 지오팜 온콜로지 인코포레이티드 filed Critical 지오팜 온콜로지 인코포레이티드
Publication of KR20150139620A publication Critical patent/KR20150139620A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
KR1020157033501A 2007-04-06 2008-04-04 이소포스포르아미드 머스타드의 염 및 이의 동족체 Withdrawn KR20150139620A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US92214807P 2007-04-06 2007-04-06
US60/922,148 2007-04-06
US92736307P 2007-05-02 2007-05-02
US60/927,363 2007-05-02
US93491407P 2007-06-15 2007-06-15
US60/934,914 2007-06-15
US123707P 2007-10-30 2007-10-30
US61/001,237 2007-10-30
PCT/US2008/004449 WO2008124097A2 (en) 2007-04-06 2008-04-04 Salts of isophosphoramide mustard and analogs thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137008586A Division KR101604244B1 (ko) 2007-04-06 2008-04-04 이소포스포르아미드 머스타드의 염 및 이의 동족체

Publications (1)

Publication Number Publication Date
KR20150139620A true KR20150139620A (ko) 2015-12-11

Family

ID=39387443

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157033501A Withdrawn KR20150139620A (ko) 2007-04-06 2008-04-04 이소포스포르아미드 머스타드의 염 및 이의 동족체
KR1020137008586A Expired - Fee Related KR101604244B1 (ko) 2007-04-06 2008-04-04 이소포스포르아미드 머스타드의 염 및 이의 동족체
KR1020097023032A Expired - Fee Related KR101505415B1 (ko) 2007-04-06 2008-04-04 이소포스포르아미드 머스타드의 염 및 이의 동족체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020137008586A Expired - Fee Related KR101604244B1 (ko) 2007-04-06 2008-04-04 이소포스포르아미드 머스타드의 염 및 이의 동족체
KR1020097023032A Expired - Fee Related KR101505415B1 (ko) 2007-04-06 2008-04-04 이소포스포르아미드 머스타드의 염 및 이의 동족체

Country Status (22)

Country Link
US (2) US8604007B2 (cg-RX-API-DMAC7.html)
EP (2) EP2155682B1 (cg-RX-API-DMAC7.html)
JP (1) JP5659010B2 (cg-RX-API-DMAC7.html)
KR (3) KR20150139620A (cg-RX-API-DMAC7.html)
CN (2) CN102942589B (cg-RX-API-DMAC7.html)
AU (1) AU2008236684B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809999A2 (cg-RX-API-DMAC7.html)
CA (1) CA2684747A1 (cg-RX-API-DMAC7.html)
CY (1) CY1116596T1 (cg-RX-API-DMAC7.html)
DK (2) DK2155682T3 (cg-RX-API-DMAC7.html)
ES (1) ES2547302T3 (cg-RX-API-DMAC7.html)
HU (1) HUE025949T2 (cg-RX-API-DMAC7.html)
IL (2) IL201424A (cg-RX-API-DMAC7.html)
MX (1) MX2009010820A (cg-RX-API-DMAC7.html)
NZ (1) NZ580341A (cg-RX-API-DMAC7.html)
PL (1) PL2155682T3 (cg-RX-API-DMAC7.html)
PT (2) PT2581367E (cg-RX-API-DMAC7.html)
RU (1) RU2527531C2 (cg-RX-API-DMAC7.html)
SI (1) SI2155682T1 (cg-RX-API-DMAC7.html)
TW (2) TWI490226B (cg-RX-API-DMAC7.html)
WO (1) WO2008124097A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907722B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585125C (en) * 2004-10-25 2014-04-22 Lee Morgan Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US7964583B2 (en) * 2006-02-17 2011-06-21 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
KR20150139620A (ko) 2007-04-06 2015-12-11 지오팜 온콜로지 인코포레이티드 이소포스포르아미드 머스타드의 염 및 이의 동족체
SG183657A1 (en) 2008-07-31 2012-09-27 Ziopharm Oncology Inc Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
WO2010099213A1 (en) * 2009-02-24 2010-09-02 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
US20130196000A1 (en) * 2012-01-31 2013-08-01 Ziopharm Oncology, Inc. Combination therapy including isophosphoramide mustard, analogs, or salts thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU427945A1 (ru) 1972-07-24 1974-05-15 Институт элементоорганических соединений СПОСОБ ПОЛУЧЕНИЯа ПОЛИФТОРАЛКИЛЗАМЕЩЕННЫХБЕНЗИЛДИХЛОРФОСФАТОВ
JPS5159886A (cg-RX-API-DMAC7.html) 1974-11-20 1976-05-25 Shionogi Seiyaku Kk
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5055459A (en) * 1986-06-30 1991-10-08 Board Of Regents, The University Of Texas Selective elimination of malignant cells from bone marrow by bis (acyloxy) propylphosphoramidates
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
WO1993021173A1 (en) 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
US5468499A (en) * 1993-11-15 1995-11-21 Ohio State University Liposomes containing the salt of phosphoramide mustard and related compounds
US5659061A (en) * 1995-04-20 1997-08-19 Drug Innovation & Design, Inc. Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities
DK0795334T3 (da) * 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
JP4629238B2 (ja) * 1999-05-24 2011-02-09 サザン・リサーチ・インスティテュート イソホスホアミドマスタード・アナログ及びその使用
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
AU2001248201B2 (en) 2000-04-13 2006-12-14 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
CA2585125C (en) * 2004-10-25 2014-04-22 Lee Morgan Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
KR20150139620A (ko) 2007-04-06 2015-12-11 지오팜 온콜로지 인코포레이티드 이소포스포르아미드 머스타드의 염 및 이의 동족체

Also Published As

Publication number Publication date
CN101679265B (zh) 2014-10-29
EP2581367A2 (en) 2013-04-17
SI2155682T1 (sl) 2015-11-30
CN102942589B (zh) 2016-04-20
TWI501972B (zh) 2015-10-01
WO2008124097A2 (en) 2008-10-16
CA2684747A1 (en) 2008-10-16
HUE025949T2 (en) 2016-05-30
EP2581367A3 (en) 2013-07-03
US20080255056A1 (en) 2008-10-16
US9340563B2 (en) 2016-05-17
KR101505415B1 (ko) 2015-03-25
MX2009010820A (es) 2010-03-18
EP2155682A2 (en) 2010-02-24
IL223353A (en) 2016-02-29
RU2527531C2 (ru) 2014-09-10
EP2581367B1 (en) 2015-12-30
IL201424A0 (en) 2010-05-31
AU2008236684A1 (en) 2008-10-16
AU2008236684B2 (en) 2013-04-18
TW200906842A (en) 2009-02-16
WO2008124097A3 (en) 2008-12-24
KR101604244B1 (ko) 2016-03-17
US20140194377A1 (en) 2014-07-10
PT2155682E (pt) 2015-10-15
JP5659010B2 (ja) 2015-01-28
TWI490226B (zh) 2015-07-01
BRPI0809999A2 (pt) 2014-10-14
IL201424A (en) 2016-02-29
PT2581367E (pt) 2016-03-28
ZA200907722B (en) 2010-11-24
RU2009140904A (ru) 2011-05-20
DK2581367T3 (en) 2016-03-14
CN102942589A (zh) 2013-02-27
DK2155682T3 (en) 2015-09-21
IL223353A0 (en) 2013-02-03
US8604007B2 (en) 2013-12-10
CN101679265A (zh) 2010-03-24
TW201406772A (zh) 2014-02-16
KR20130041391A (ko) 2013-04-24
CY1116596T1 (el) 2017-03-15
NZ580341A (en) 2012-06-29
EP2155682B1 (en) 2015-06-24
PL2155682T3 (pl) 2015-12-31
JP2010523571A (ja) 2010-07-15
ES2547302T3 (es) 2015-10-05
KR20090130098A (ko) 2009-12-17

Similar Documents

Publication Publication Date Title
HK1209752A1 (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
KR101604244B1 (ko) 이소포스포르아미드 머스타드의 염 및 이의 동족체
ES2565069T3 (es) Sales de mostaza de isofosforamida y análogos de las mismas
AU2011221388B2 (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US7964583B2 (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
HK1185884A (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
HK1100945B (en) Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20151124

Application number text: 1020137008586

Filing date: 20130403

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid